Emcure’s Subsidiary Company Tillomed Acquires Pharma Portfolio from Manx in £19.7 Million Deal

Tillomed Laboratories Limited, a subsidiary of Emcure Pharmaceuticals Ltd. ( NSE: EMCURE), has signed an Asset Purchase Agreement (APA) with UK-based Manx Healthcare Limited and its subsidiaries, Manx Pharma Ltd. and Manx Generics Limited.

Key Details of the Deal

Under this agreement, Tillomed will acquire Manx’s product portfolio, including dossiers, marketing authorisations, intellectual property, and inventory. The total deal value is around £19.7 million, which includes £4.7 million for inventory. Tillomed will make an initial payment of £6.2 million, with the remaining amount to be paid in milestone-based instalments over the next 18 months.

Strategic Benefits

The acquisition will help Tillomed expand its product range, strengthen its market presence, and improve patient access to essential medicines. Speaking about the deal, Ajit Srimal, CEO of Tillomed, stated, “This acquisition reinforces our commitment to providing high-quality and affordable healthcare solutions. The addition of Manx’s established products will enhance our portfolio and market reach.”

About Tillomed

Tillomed Laboratories Limited is a European pharmaceutical company specialising in the development, licensing, and marketing of generic medicines. Based in Luton, UK, Tillomed operates across multiple European countries, ensuring affordable healthcare solutions. As a subsidiary of Emcure Pharmaceuticals, Tillomed benefits from strong R&D, manufacturing, and distribution capabilities. The company has a diverse portfolio of over 100 products, making quality medicines more accessible across Europe.

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune, India. It focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products globally. It ranks as the 12th largest pharmaceutical company in India (as of June 2024) and operates in over 70 countries, including Europe and Canada.

This acquisition marks a significant step for Tillomed and Emcure, strengthening their position in the European market and expanding their product offerings.

As of April 4, 2025, at 12:38 PM IST, Emcure Pharmaceuticals share price (NSE: EMCURE) is trading at ₹994.85, down ₹38.40 (-3.72%) for the day. The stock opened at ₹1,037.50, reached a high of ₹1,047.95, and a low of ₹988.55. Emcure has a market capitalisation of ₹18,850 crore, a P/E ratio of 31.30, and no recorded dividend yield. The stock’s 52-week high stands at ₹1,580.00, while its 52-week low is ₹910.95.

Conclusion

This acquisition reinforces Tillomed’s commitment to delivering high-quality, affordable medicines while strengthening Emcure’s footprint in the European market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.